A phase II clinical trial testing trastuzumab and nivolumab in combination with either ipilimumab or mFOLFOX6 for previously untreated HER2-positive esophagogastric adenocarcinoma found a higher incidence of irAEs and poorer treatment outcomes with ipilimumab combination therapy compared to mFOLFOX6 [195]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.